BLENREP (belantamab mafodotin-blmf) for Multiple Myeloma

BLENREP is an injection available as a prescription used to treat adults with multiple myeloma who:

• have received at least 4 prior medicines to treat multiple myeloma, and
• their cancer did not respond to prior treatment or has come back.

It is not known if BLENREP is safe to use in children.

None.

Before receiving BLENREP, tell your healthcare provider about all of your medical conditions, including if you:

• have a history of vision or eye problems.

• have bleeding problems or a history of bleeding problems.

• are pregnant or planning to become pregnant. BLENREP can harm your unborn baby.

• Females who are able to become pregnant:
  • Your doctor may do a pregnancy test before you start treatment with BLENREP
  • You should use birth control during treatment with BLENREP and for 4 months after the last dose. Talk to your doctor about the different birth control methods you can use during this time.
  • Tell your doctor if you become pregnant or think you may be pregnant during treatment with BLENREP.

• Males with female partners who are able to become pregnant should use birth control during treatment with BLENREP and for 6 months after the last dose.

• are breastfeeding or planning to breastfeed. It is not known if BLENREP can pass into your breast milk. Do not breastfeed during treatment with BLENREP and for 3 months after the last dose.

• BLENREP may affect fertility in males and females.

• Tell your doctor about all the medicines prescriptions, over-the-counter medicines, vitamins, and herbal supplements you take.

• BLENREP will be given to you by your doctor by intravenous infusion into your vein over approximately 30 minutes.

• BLENREP is usually given every 3 weeks.

• Your doctor will decide how many treatments you may need.

• Your doctor may decrease your dose, temporarily stop or completely stop treatment with BLENREP if you have serious side effects.

• If you miss any appointments, call your doctor.

What are the common side effects of BLENREP?

The most common side effects of BLENREP include nausea, low blood cell counts, vision or eye changes such as findings on eye exam (keratopathy), fever, infusion-related reactions, decreased vision or blurred vision, tiredness, and changes in kidney or liver function blood tests.

What are the serious side effects of using BLENREP?

• Eye problems: Eye problems are common with BLENREP and can lead to blurred vision, dry eyes, worsening vision, corneal ulcer, and severe vision loss. Tell your doctor if you have any vision changes or eye problems during treatment with BLENREP:
  • Your doctor will send you to an eye specialist to check your eyes before you start treatment with BLENREP, prior to each dose of BLENREP, and for worsening symptoms of eye problems.
  • Even if you feel your vision seems fine, it is crucial that you get your eyes checked during treatment with BLENREP because some changes can happen without symptoms and may only be seen on an eye exam.
  • Make sure to use preservative-free lubricant eye drops at least 4 times per day during treatment with BLENREP as instructed by your doctor.
  • Be cautious when driving or operating machinery as BLENREP may affect your vision.
  • Do not wear contact lenses during treatment with BLENREP. Ask your doctor

• A decrease in platelets: is common with BLENREP and can be serious. Your doctor will check if your blood cell counts are normal before you start treatment with BLENREP and during treatment. Tell your doctor if you have bleeding or bruising during treatment with BLENREP.

• Infusion reactions: Infusion reactions are common with BLENREP and can be serious. Tell your doctor right away if you experience any of the symptoms of an infusion reaction while receiving BLENREP:
  • chills or shaking
  • redness of your face (flushing)
  • itching or rash
  • shortness of breath, cough, or wheezing
  • swelling of your tongue, lips, throat, or face
  • dizziness
  • feel like passing out
  • tiredness
  • fever
  • feel like your heart is racing (palpitations)

Active Ingredient: belantamab mafodotin-blmf
Inactive Ingredients: citric acid, edetate dihydrate, polysorbate 80, disodium, trehalose dihydrate,
trisodium citrate dihydrate.